This study characterizes the early steps of T lymphocyte activation in healthy elderly subjects. The expression of CD69, the earliest inducible antigen which appears with T lymphocyte activation, was assessed in T cells cultured with medium, anti-CD3 or PMA. The proliferative responses of T cells stimulated through CD69 and CD3 pathways were also studied. Donors included 31 healthy elderly [age mean (SD) 80 (8) CD69 T cell expression was equal in both groups with 2 ng/ml of PMA, but the co-stimulatory responses to CD69 under these conditions and in the presence of anti-CD3 were lower in the aged (16914 vs. 28904 cpm, p < 0.02) and (6944 vs. 14370 cpm, p < 0.02) respectively. Aged T cells failed to express CD25 at the same levels of young T cells when stimulated with CD69.
Introduction
Immunosenescence is associated with a deterioration of both cellular and humoral immunity [1] , and may contribute to the age-related increase in tumours and infectious diseases [2, 3] . The abnormal T cell function associated with human ageing is characterized by a poor proliferative T cell response to different mitogens and antigens, a poor T-helper function, and a defective generation of cytolytic effector cells [4] [5] [6] . These abnormal in vitro responses are detected several days after the triggering stimuli and may be influenced by defects occurring in the earlier phases of the immune process [7, 8] . However, little is known about the effect of ageing on these earlier phases.
The CD69 molecule, the earliest marker of T cell activation, is a member of the C-type animal lectin superfamily of signal transmitting receptors and has recently been cloned [9, 10] . This molecule is synthesized de novo and is expressed upon T lymphocyte activation with a wide variety of stimuli [protein kinase C (PKC) activators, anti-CD3, anti-CD2, anti-CD5 and/or anti-CD28 monoclonal antibodies (mAbs)] [11] [12] [13] [14] . The regulation of CD69 expression is of great interest. It is undetectable in resting peripheral blood T lymphocytes and is expressed only 30-60 minutes after stimulation. The peak expression is reached at 24 hours, then gradually decreases over 72 hours [15, 16] .
CD69 functions as a co-stimulatory molecule for T cells. Once CD69 is expressed in response to submitogenic doses of phorbol esters, the addition of mAbs against CD69 triggers cell proliferation [15] .
The regulation and expression of CD69, compared with other activation antigens, provide a new approach to the analysis of T cell activation and function in elderly subjects. The present study was undertaken to characterize the initial steps of T lymphocyte activation in healthy aged people. The expression and function of the CD69 antigen was compared between healthy elderly and young subjects. Our results show that in healthy elderly humans, T cell activation is abnormal from its earliest phases.
Subjects and Methods
Subjects: The participants in this study were 31 (11 men and 20 women) healthy old [age: mean (SD) 85 (8) years] and 33 (12 men and 21 women) healthy young [age 30 (5) ] volunteers. Old subjects fulfilled the criteria of the Senieur Protocol [17] for immunological studies in elderly subjects. Informed written consent was obtained in all cases.
Cell preparation: Samples were drawn into heparinized syringes. Peripheral blood mononuclear cells (PBMC) were isolated on Ficoll-Hypaque gradients centrifugation, and resuspended in RPMI 1640 culture medium (Flow Laboratories, Irvine, Scotland), supplemented with 10% foetal calf serum [(FCS), GIBCO BRL, Paisley, Scotland], penicillin (100 U/ml), streptomycin (lOOmg/ml), and 2mM glutamine (complete culture medium).
CD69 induction assay: PBMC were resuspended at 5 x 10 6 cells in complete culture medium in 10 ml round-bottom culture tubes (Greiner-Soria No 163160, Madrid, Spain). Each of the experimental groups was supplemented to a final volume of 0.5 ml either with medium alone, 454mAb (IgG2a murine anti-human CD3, 1/10 dilution of hybridoma supernatant [18] ) or phorbol myristate acetate [(PMA), Sigma Chemical Co., 10ng/ml]. The cells were incubated in humidified atmosphere containing 5% CO 2 for 18 hours at 37°C. After extensive washing with Hank's solution (GIBCO BRL), the PBMC were further purified by rosetting for 1 h at 4°C with neuraminidase-treated sheep red blood cells (N-SRBC), using a modification of a previously described method [19] . The rosetting (E + ) and non-rosetting population were separated by Ficoll-Hypaque gradient centrifugation. An enriched T cell population was obtained after lysis of the SRBC with dH 2 O and washing in Hank's solution. The E + cells were assessed for surface CD69 expression by flow cytometry as described below. In some experiments the cells were activated in parallel with either soluble or immobilized anti-CD3 mAb. For this purpose, 96-well flat-bottomed plates were coated overnight at 4°C with F(ab )2 fragments of a goat anti-mouse IgG (Sigma) in Tris-buffer (pH 8.2) at a concentration of 7.5/ig/ml. The plates were washed three times with phosphate-buffered saline (PBS), and then were incubated with complete culture medium for 1 h. After washing again, the plates were incubated for 1 h at room temperature with saturating concentrations of the 454 (anti-CD3) mAb. After washing three times, the cells were added and cultured for 18 h before being stained.
Staining: All procedures were done at 4°C. After washing again in phosphate-buffered saline plus 1% bovine serum albumin (PBS-BSA), the E + cells were assessed for cell surface CD69 by indirect immunofluorescence using Tp 1/56 mAb (IgG murine anti-human CD69mAb, provided by Prof. Francisco Sanchez-Madrid, Hospital de la Princesa, Madrid) followed by fluorescein-conjugated (F(ab )2 fragments of goat anti-mouse IgG (Kallestad, Austin, TX, USA). In some experiments, cells were double stained using as first antibody either the fluorescein-conjugated anti-CD3 or anti-CD5 mAb (Coulter) and after extensive washing in PBS, the cells were incubated with the second antibody, a biotinylated anti-CD69 mAb (TP 1/55) followed by 10% phycoerythrin labelling.
Cell fluorescence was analysed using an EPICS Profile II (Coulter Electronics, Hialeah, FL, USA), gating the lymphocyte population (which excluded monocytes) and counting 5 x 10 cells per sample. The results are expressed as percentage of E + or CD3 + /CD5 + cells expressing CD69 after subtraction of background fluorescence (cells incubated with PBS-BSA followed by the fluorescein conjugated goat antimouse IgG or fluorescein/biotinylated isotype matched antibodies plus phycoerythrin 10%). Antigen density was indirectly ascertained assessing the mean fluorescence intensity (MFI) of the positive population. Fluorescence intensity for different mAbs was determined on a logarithmic scale, and data for MFI were converted to arbitrary linear units. The experiments were selected for analysis when the percentage of CD3 + cells on the E + population was > 85%, and the background staining was < 5% as assessed by flow cytometry. In some experiments PBMC were cultured in the presence of the stimuli described above, and the kinetics of CD69 expression were analysed in aged and young T cells by flow cytometry at 18, 42 and 66 h.
Proliferation assay: PBMC from healthy donors and aged subjects were cultured at a concentration of 2x10 cells/ 200^1 in complete culture medium. Cells were activated in triplicate cultures, in 96 flat-bottomed microtitre plates (Costar, High Wycombe, England) and maintained at 37°C in a humidified atmosphere containing 5% CO2 for 72 h. Anti-CD3 mAb (OKT3, Ortho diagnostic System, Milan, Italy), PMA (2ng/ml), rIL-2 (lOIU/ml, Sigma Chemical Co.) and/ or anti-CD69 TP 1/8X (10/ig/ml, provided by Prof. Francisco Sanchez-Madrid) were used as stimulators. In some experiments, the OKT3 mAb was immobilized in plastic plates as described above and used for the proliferation assay in parallel with the soluble anti-CD3. Cell proliferation was estimated by [ 3 H]TdR (1/iCi = 37 KBq, Amersham Life Sciences, Buckinghamshire, England) incorporation during the last 16 hours of culture. Cells were harvested and the radioactivity was measured in a direct /3-counter MATRIX 96 (Packard Instrument Co. Mariden, CO., USA). Cell viability was determined by cell counting microscopically with trypan blue.
Kinetics of CD25 expression: T cells were further purified by negative selection using magnetic anti-mouse IgG beads (Immunotech, Marseille Cedex, France) conjugated with anti-CD14 (Immunotech), anti-OKMl (Ortho Diagnostic Systems Inc., Raritan, NJ, USA) and anti-HLA-DR (Q2.70, provided by Dr F. Diaz-Espada, Clinica Puerta de Hierro, Madrid). PB purified T cells were activated and cultured in 96 flat-bottomed microtitre plates for 160h in the presence of medium alone, PMA (2ng/ml) or PMA plus anti-CD69 mAb (Tp 1/8X). Cells were then extensively washed in PBS and stained at 4°C for 1 h with phycoerythrin (PE)-labelled anti-CD25. PE-labelled mouse IgG of the same isotype was used as control. The expression of CD25 was assessed by flow cytometry at different time points of the culture (0, 16, 37, 61 and 86 h) subtracting the fluorescence background of the control IgG. Antigen density was indirectly ascertained assessing the mean fluorescence intensity (MIF) described above.
Statistical analysis: The normality of the variables analysed was tested with the Shapiro-Wilk test. The data are reported as the mean (SD) upon conditions of normality and median [quantiles when the variables did not fit a Gaussian distribution. Normal variables were compared using Student's t test and non-parametric variables using the Mann-Whitney U test.
Results

In vivo activation of aged peripheral blood (PB) T cells:
Using CD69 as a marker we evaluated the ongoing in vivo activation status of PB T cells from aged and young subjects. Freshly isolated PBMC were cultured for 18 h with medium and, after rosetting, the E + population was assessed for CD69 expression by flow cytometry. As shown in Figure 1 , the percentage of PB T cells that expressed CD69, after subtraction of background fluorescence, was lower in old than young subjects [3.4% (1.6-5.9) vs. 10% (6-18), p < 0.0003]. Both groups expressed CD69 with a very low intensity of fluorescence ( Figure 6 , MFI 1.1 and 1.07 respectively). Differences were not influenced by CD2 crosslinking during the rosetting procedure since similar results were obtained in double staining experiments of fresh, unfractionated PBMC (data not shown). These results [15]. Freshly obtained aged and control PBMC were cultured for 18 h with anti-CD3 mAbs or PMA and, after resetting, the E population was stained with anti-CD69 mAbs. As illustrated in Figure 2 , when cultured with anti-CD3 mAbs, the percentage of PB T cells expressing CD69 was lower in the old subjects [28.1% Figure 3 , when cultured with lOng/ml of PMA, the expression of CD69 tended to be lower in the aged [84.5% (70.9-94.9) vs. 99% (65.7-100), p = 0.051], and the MFI (Figure 6 ) was significantly lower in the aged [ 1.31 (1.24-1.64) To exclude a deficient crosslinking of soluble anti-CD3 mAbs due to poor E" Fc receptor function as the cause of the impaired CD3-induced CD69 expression on aged PB T cells, young and aged PBMC were cultured in parallel with either soluble or immobilized anti-CD3 mAbs. CD69 expression was similar in each subject with either type of anti-CD3 mAbs, maintaining the differences between young and aged T cells (data not shown). The differences observed after activation through the CD3 pathway between aged and young subjects could not be attributed to differences in the basal expression of CD69, as the differences persisted after subtracting the basal values from the post-stimulation values in paired samples.
Time course of CD69 expression: To rule out the possibility that the defective anti-CD3 activation in the elderly was due to slower kinetics of CD69 expression, we analysed the CD69 expression in anti-CD3 activated T cells after 18, 42, and 66 hours of culture in three aged and three young subjects. The differences between aged and young subjects persisted at all these time points as shown in Figure 4 .
Proliferation assays: CD69 works as a co-stimulatory pathway for T cells, as anti-CD69 mAbs are able to trigger IL-2 synthesis, IL-2R expression, and cell proliferation only when the PKC is simultaneously activated with phorbol esters [15] . In order to study the CD69 activation pathway in elderly subjects, and compare it with the TcR/CD3 activation pathway [20, 21] , we assessed the proliferative responses of young and aged PBMC after culture with anti-CD3 mAbs and a combination of PMA and anti-CD69 mAbs. As shown in the Table, the proliferative response to anti-CD3 mAbs is decreased in the elderly (9560 vs. 17393 cpm, p < 0.02). This defect was not corrected by the addition of IL-2 (15969 vs. 23308 cpm, p < 0.03) or with co-culture with anti-CD69 mAbs (6944 vs. 14370 cpm, p <0.02).
As shown in the Table, the proliferation through the PBMC from young and aged subjects were cultured at a concentration of 2 x 10 5 cells/200/il in complete culture medium. Cells were activated in triplicate cultures with anti-CD3 mAbs, PMA (2 ng/ml), rIL-2 (10 IU/ml) and anti-CD69 mAbs. Cell proliferation was estimated by [ 3 H]TdR incorporation during the last 16 h of culture. Results are expressed as cpm and represent the mean (standard deviation) in 10 young and 10 aged subjects. Cell viability as assessed by tripan blue staining was always above 85%.
CD69 molecule in the presence of submitogenic doses of PMA (2 ng/ml) was also decreased in the elderly (16914 vs. 28904 cpm, p < 0.02), and was not changed by the addition of rIL-2 (18197 vs. 30519 cpm, p < 0.005). We ruled out a defective surface expression of CD69 as the possible cause of the impaired anti-CD69 response, because the CD69 expression on PBMC after culture with 2 ng/ml of PMA was similar in young and old both in percentage and MFI.
CD25 expression after stimulation through CD69: The CD69-induced T cell proliferation is IL-2/CD25 dependent [15] . As the addition of rIL-2 did not correct the impaired CD69-induced proliferative response (Table) , a defective CD25 expression might be involved in this phenomenon. To explore this possibility, we studied CD25 expression on aged and young purified T cells after stimulation with PMA, anti-CD69, and anti-CD69 plus PMA. CD25 expression was assessed by flow cytometry at 0, 16, 37, 61 and 86 h. As illustrated in Figure 5 , the percentage of T cells expressing CD25 was comparable in young and aged at all time points, with a peak expression between 37 and 61 h. However, at the 37-h point, the aged T cells expressed CD25 with a markedly lower MFI, reflecting a lower antigen density in this population ( Figure 6 ).
Our results suggest that a defective IL-2Ra expression might be involved in the abnormal CD69-induced aged T cell proliferation.
Discussion
This study was designed to analyse the very first steps of T lymphocyte activation in healthy elderly subjects. We assessed the expression and functionality of the CD69 molecule, the earliest surface antigen appearing after T cell activation [22] .
We first studied the in vivo activation status of aged PB T cells. Our results show a defective CD69 expression, suggesting a decreased percentage of recently activated T lymphocytes. This finding contrasts with the normal expression in unstimulated aged T cells of other intermediate and late activation antigens, like IL-2Ra (CD25), transferrin receptor, 4F2 or HLA-DR [23, 24] . This divergence might reflect the different degrees of stimulation needed for the appearance or up-regulation of the various surface molecules, as suggested by two facts: (a) in vitro CD69 induction has less stringent requirements than other activation antigens [11, 15, 25] ; and (b) a similar differential expression has been shown in different in vivo physiological and pathological conditions [26] [27] [28] [29] [30] . Independently of the functional significance of low intensity CD69 expression in young and old, our results could indirectly reflect a decreased T cell response to in vivo activation signals, a hypothesis that needs to be addressed by analysis of CD69 expression in different lymphoid tissues.
We then studied the responses of aged T cells in a series of in vitro CD69 induction experiments. The expression of CD69 was impaired with anti-CD3 mAbs, better, though still abnormal, with optimal concentrations of PMA, and normal with low doses of PMA. Similar to a previous study [31] , we showed that the aged T cells are not intrinsically hypo-responsive. The expression of CD69 on T lymphocytes depends on PKC translocation and activation. The low CD69 induction with anti-CD3 mAbs was improved by direct PKC activation by PMA, suggesting that the aged T cells have a defective generation of one or several intracellular second messengers in the TcR/ CD3 to PKC pathway [32] [33] [34] . Impaired calcium mobilization, DAG production, and PKC translocation in lectins or anti-CD3-stimulated aged T cells have been suggested in several studies [7, [35] [36] [37] [38] [39] . However, in our study we cannot rule out a primary defect of PKC, manifested only under culture conditions of maximal direct activation.
The impaired anti-CD3-induced CD69 expression in the aged was not the consequence of a diminished CD3 expression on elderly T cells (data not shown). In contrast to other systems [40, 41] , neither the different
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Hours in culture kinetics of CD69 expression and modulation nor a poor Fc receptor function in the E~ population seemed to play a role in this defect, as suggested by the persistent difference between young and old in the time-course experiments (see Figure 4) , and the inability of immobilized anti-CD3 to induce a normal CD69 expression, respectively.
In the next group of experiments, we studied the ability of the CD69 molecule to act as a co-stimulatory pathway in the elderly. As previously shown [5, 18, 23, 25, 42, 43] , when cultured in the presence of anti-CD3, the proliferative response was significantly lower in aged T cells. This, together with the poor CD69 induction response, supports the hypothesis of a defect in the signal transmission through the TcR/CD3 pathway. The co-culture of anti-CD3-stimulated aged T cells with anti-CD69 mAbs did not increase the proliferative response, in young and old. When T cells were cultured in the presence of suboptimal doses of phorbol esters and anti-CD69, a combination that triggers cell proliferation [11, 15] , the response was significantly lower in the aged, suggesting that the CD69 co-stimulatory pathway is impaired in the elderly, independently of TcR-CD3 stimuli. We found that young and old expressed similar amounts of CD69 after culture with low doses of PMA, pointing to a defect in the CD69 signal transduction mechanisms as one of the causes of low CD69-induced proliferation in elderly subjects.
When we analysed the ability of CD69 to induce the appearance of high affinity IL-2R, we found that after PBL culture with low-dose PMA and anti-CD69, aged donors expressed CD25 with a significantly lower MFI than controls. A similar poor IL-2R induction has been found after activation with anti-CD3 mAbs [5] . Low IL-2R expression in older subjects might be related not only to a lower degree of activation but also to a lower amount of IL-2 in the media. Although we did not directly test for IL-2 secretion in our experiments, the addition of exogenous rIL-2 to the cultures did not revert the impaired proliferation observed through either the CD69 or the CD3 pathways, suggesting that a decreased production of IL-2 is not the only cause of this defect. An alternative explanation of our results might be the diminished number of activated T cells able to respond to saturating doses of rIL-2 [44, 45] .
In this study we have described two separate functional defects during the early phases of aged T cell activation. First, an impaired CD69 expression after CD3-stimulation, and second, a defective CD69 co-stimulatory function. Anti-CD3-mediated events are well known and include phospholipase C activation, diacyl-glycerol generation, cytosolic free calcium increase, and PKC activation. However, the biochemical steps mediating CD69 signalling are only partially known. CD69 is found in association with a GTPbinding protein [12] and its crosslinking leads to an increase in cytosolic calcium, similar to other costimulatory pathways [11] . A defect in a common step shared between the CD3 and CD69 activation pathways might be the origin of both the inductive and the signalling defects in the elderly [31, 35] . This hypothesis is supported by two facts: first, the lack of increase in cell proliferation after co-stimulation of anti-CD3 activated T lymphocytes with CD69 (which points to the existence of a common intermediate mediator that is maximally activated with optimal doses of anti-CD3) and second, the apparent normality of the CD28 stimulation pathway that acts, mostly independent of the PKC pathway [46] , in an elderly population (Vidan, Serra et al. unpublished).
The impaired T cell responsiveness found in the CD69 pathway might be influenced by changes in the lymphocyte populations associated with ageing. The CD4/CD8 co-receptor and the different isoforms of the transmembrane tyrosine specific phosphatase CD45 appear to act by potentiating the initial TcR/CD3 complex signalling [47, 48] , while other co-stimulatory molecules like CD2, CD5, CD69 and CD28 act later in concert with the initial signal leading to a complete T cell activation [13, 49, 50] . Shifts from naive (CD45RA) to memory (CD45RO) T cell predominance with age [51, 52] are paralleled by functional changes, including decreased proliferation of T cells in response to TCR and co-stimulus-mediated stimulation, and alterations in the profiles of cytokines produced in response to T cell activation [53] [54] [55] . It has been suggested that the increased expression of the low-molecular-weight isoforms of CD45 might induce a different sensitivity to TcR/CD3 signals that could influence some of the changes found in early transduction events [31, 34] and could also influence the CD69 co-stimulatory molecule. The individual analysis of the multiple pathways involved in signal transduction might help to reveal the molecular basis and the exact biochemical steps responsible for the defective aged lymphocyte responses.
